Removing barriers to a clinical pharmacogenetics service

Personalized Medicine

Volumn 5, Issue 5, 2008, Pages 471-480

  Newman, William ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Clinical service; Evidence level; Guidlines; Pharmacogenetics

Indexed keywords

ABACAVIR; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AROMATASE INHIBITOR; AZATHIOPRINE; CARBAMAZEPINE; CETUXIMAB; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FORMOTEROL; GLUCURONOSYLTRANSFERASE 1A1; HLA B ANTIGEN; HLA B15 ANTIGEN; HLA B57 ANTIGEN; IMATINIB; IRINOTECAN; K RAS PROTEIN; MITOCHONDRIAL DNA; PANITUMUMAB; SALMETEROL; SEROTONIN UPTAKE INHIBITOR; STEM CELL FACTOR RECEPTOR; TAMOXIFEN; THIOPURINE METHYLTRANSFERASE; TRASTUZUMAB; UNCLASSIFIED DRUG; WARFARIN;

ADJUVANT THERAPY; ASTHMA; BREAST CANCER; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUING EDUCATION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; CYSTIC FIBROSIS; DRUG HYPERSENSITIVITY; DRUG SAFETY; EDUCATION PROGRAM; GENE DOSAGE; GENETIC SCREENING; GENOTYPE; HEALTH CARE AVAILABILITY; HEARING LOSS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR GENETICS; MUTATIONAL ANALYSIS; NEUTROPENIA; PHARMACOGENETICS; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SOMATIC MUTATION; STEVENS JOHNSON SYNDROME; ULCERATIVE COLITIS;

EID: 56149097636     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/17410541.5.5.471     Document Type: Review

References (53)

1. Mallal S, Phillips E, Carosi G et al.; PREDICT-1 Study Team: HLA -B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358(6), 568-579 (2008).
2. Hughes AR, Spreen WR, Mosteller M et al.: Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility. Pharmacogenomics J. (2008) (Epub ahead of print)
3. Lennard L, van Loon JA, Lineyman JS, Weinshilboum RM: Thiopurine pharmacogenetics In leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin. Pharmacol. Ther. 41(1), 18-25 (1987).
4. Leonard L, van Loon JA, Weinshilboum RM: Pharmacogenetics of acute AZA toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin. Pharmacol. Ther. 46(2), 149-154 (1989).
5. Tan BB, Lear JT, Gawkrodger DJ. English JSC: Azathioprine in dermatology: a survey of current practice in the UK. Br. J. Dermatol. 136(3), 351-355 (1997).
6. Holme SA, Duley JA, Sanderson J et al.: Erythrocyte thiopurine methyl transferase assessment prior to AZA use in the UK. Q. J. Med. 95(7), 439-444 (2002).
7. Fargher EA, Tricker K, Newman W et al.: Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. J. Clin. Pharm. Ther. 32(2), 187-195 (2007).
8. Marshall E: Preventing toxicity with a gene test. Science 302(5645), 588-590 (2003).
9. Colombel J-F, Ferrari N, Debuysere H, et al.: Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 118(6), 1025-1030 (2000).
10. Konstantopoulou M, Belgi A, Griffiths KD, Seale JR, Macfarlane AW. Azathioprine-induced pancytopenia in a patient with pompholyx and deficiency of erythrocyte thiopurine methyltransferase. BMJ 330(7487), 350-351 (2005).
11. Tucker G: Pharmacogenetics - expectations and reality. BMJ 9329(7456). 4-6 (2004).
12. The Royal Society: Pharmacogenetics: The Hopes and Realities of personalized Medicines. A Guide for Health Professionals. The Royal Society, London. UK (2005).
13. Lunshof JE, Pirmohamed M, Gurwitz D: Personalized medicine: decades away? Pharmacogenomics 7(2), 237-241 (2006).
14. Shah J: Criteria Influencing the clinical uptake of pharmacogenomic strategies. BMJ 328(7454), 1482-1486 (2004).
15. Department of Health and Human Services: Realizing the Potential of Pharmacogenomics: Opportunities and Challenges. Report of the Secretary's Advisory Committee on Genetics, Health and Society (2008).
16. Hedgecoe AM: Context, ethics and pharmacogenetics. Stud. Hist. Phil. Biol. Biamed. Sci. 37(3), 566-582 (2006).
17. Webster A, Martin P, Lewis G, Smart A: Integrating pharmacogenetics into society: in search of a model. Nat. Rev. Genet. 5(9), 663-669 (2004).
18. Woolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J: Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines. BMJ 318(7182), 527-530 (1999).
19. McGlynn EA, Asch SM. Adams J et al.: The quality of health care delivered to adults in the United States. N. Eng. J. Med. 348(26), 2635-2645 (2003).
20. Anstey AV, Wakelin S, Reynolds NJ; British Association of Dermatologists Therapy, Guidelines and Audit Subcommittee: Guidelines for prescribing azathioprine in dermatology Br. J. Dermatol. 151(6), 1123-1132 (2004).
21. Chakravarty K, McDonald H, Pullar T et al.: BSR & BHPR guideline for disease-modifying anti-rheumatic drug therapy (DMARD) in consultation with the British Association of Dermatologists. Rheumatology 47(6), 924-925 (2008).
22. Carter MJ, Lobo AJ, Travis SP; IBD Section, British Society of Gastroenterology: Guidelines for the management of inflammatory bowel disease in adults. Gut 53(5), V1-V16 (2004).
23. Anderson JL, Horne BD, Stevens SM et al.: Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116(22), 2563-2570 (2007).
24. Bleecker ER, Postma DS, Lawrance RM, Meyers DA, Ambrose HJ, Goldman M: Effect of ADRB2 polymorphisms on response to long-acting β2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 370(9605), 2118-2125 (2007).
25. Innocenti F, Undevia, SD, Iyer L et al.: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. 22(8), 1382-1388 (2004).
26. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL: UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J. Natl. Cancer Inst. 99(17). 1290-1295 (2007).
27. O'Dwyer PJ, Catalano RB: Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J. Clin. Oncol. 24(28), 4534-4538 (2006).
28. Carbamazepine: genetic testing recommended in some Asian populations. Drug Safety Update 1(9), 5 (2008).
29. Chung WH, Hung SI, Hong HS et al.: Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428(6982), 486 (2004).
30. Lonjou C, Thomas L, Borot N et al.: A marker for Stevens-Johnson syndrome: ethinicity matters. Pharmacogenomics J. 6(4), 265-268 (2006).
31. Man CB, Kwan P, Baum L et al.: Association between HLA-B*1502allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepda. 48(5), 1015-1018 (2007).
32. Allison M: Is personalized medicine finally arriving? Nat. Biotechnol. 26(5), 509-517 (2008).
33. Goetz MP, Kamal A, Ames MM: Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin. Pharmacol. Ther. 83(1), 160-166 (2008).
34. Punglia RS, Burstein HJ, Winer EP, Weeks JC: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J. Natl. Cancer Inst. 100(9), 642-648 (2008).
35. Gardiner SJ, Begg EJ: Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice? Pharmacogenet. Genomics 15(5), 365-369 (2005).
36. Wordsworth S, Papanicolas I, Buchanan J, Frayling I, Taylor J, Tomlinson I: Molecular testing for somatic cancer mutations: a survey of current and future testing in UK laboratories. J. Clin. Pathol. 61(3), 373-376 (2008).
37. Hedgecoe A: Education, ethics and knowledge deficits in clinical pharmacogenetics. Pharmacogenomics 8(3), 267-270 (2007).
38. Gurwitz D, Lunshof JE, Dedoussis G et al.: Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education. Pharmacogenomics J. 5(4). 221-225 (2005).
39. Newton R, Lithgow J, Li Wan Po A, Bennett C, Farndon P: How Will Pharmacogenetics Impact an Pharmacy Practice? Pharmacists' Views and Educational Priorities. National Genetics Education and Development Centre and The Royal Pharmaceutical Society of Great Britain (2007).
40. Latif DA, McKay. AB: Pharmacogenetics and phasmacogenomics. Instruction in colleges and schools of pharmacy in the United States. Am. J. Pharm. Educ. 69, 23 (2005).
41. Brazeau DA, Brazeau GA: A required course in human genomics, pharmacogenomics, and bioinformatics. Am. J. Pharm. Educ. 70, 125(2006),
42. Gage B, Eby C, Johnson J et al.: Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84(3), 326-331 (2008).
43. Fargher EA, Eddy C, Newman W et al.: Patiens' and healthcare professionals' views on pharmacogenetic testing and its future delivery in the NHS. Pharmacogenomics 8(11), 1511-1519 (2007).
44. Flowers CR, Veenstra D: The role of cost-effectiveness analysis In the era of pharmacogenomics. Pharmacoeconomics 22(8), 481-493 (2004).
45. Drummond M, Sculpher M. Torrance GW, O'Brien BJ, Stoddart G: Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press, Oxford, UK (2005).
46. Payne K: Towards an economic evidence base for pharmacogenetics: consideration of outcomes is key. Phatmacogenomics 9(1), 1-4(2008).
47. Payne K, Newman W, Fargher EA, Tricker K, Bruce I, Ollier WER: TPMT testing in rheumatology: any better than routine monitoring? Rheumatology 46(5), 727-729 (2007).
48. Veenstra DL, Harris J, Gibson RL, Rosenfeld M, Burke W, Watts C: Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes. Genet. Med. 9(10), 695-704 (2007).
49. Sculpher MJ, Drummond MF. Buxton MJ: The iterative use of economic evaluation as part of the process of health technology assessment. J. Health Serv. Res. policy 2, 26-30 (1997).
50. Ryan M, Gerard K: Using discrete choice experiments to value healthcare programmes: current practice and future research reflections. Appl. Health Econ. Health Pol. 2(1), 55-64 (2003).
51. Fargher EA, Newman W, Eddy C et al.: Exploring patients' and healthcare professionals' preferences for pharmacogenetic testing services. Presented at: Pharmacogenomics, Joint Cold Spring Harbor Laboratory/Wellcome Trust Conference. Hinxton, Cambridge, UK, 17-20 October 2007.
52. Hedgecoe AM: The Politics Personalised Medicine - Pharmacogenetics in the Clinic. Cambridge University Press. Cambridge, UK (2004).
53. Hedgecoe AM: From resistance to usefulness: sociology and the clinical use of genetic tests, BioSocieties 3(2), 183-194 (2008).